@entity900 plus @entity7324 in XXXX : a phase II trial of the EORTC Breast Cancer Cooperative Group.

@entity1 @entity8 @entity7324 @entity0 @entity900
This phase II clinical trial was conducted in a series of @entity1 with @entity0 , refractory to conventional chemotherapy. The therapeutic regimen consisted of a combination of @entity900 100 mg/m2, given as a 24-hr infusion on day 1 and @entity7324 (VDS) 2 mg/m2, i.v. bolus on days 1 and 8. VDS injection was omitted on day 8 in @entity1 with poor bone marrow reserves (prior extensive irradiation). Courses were repeated at 4-week intervals until documented disease progression. Among 46 evaluable @entity1 , there were two complete and seven partial remissions for an overall response rate of 20%. These responses lasted for a median of 21 weeks (range 8-89 weeks). Remission rates according to the predominant metastatic site were as follows: soft tissue, 3/8 (38%); bone, 0/6 (0%); viscera, 6/32 (19%). Transient myelosuppression and gastrointestinal intolerance were almost universal. @entity8 and neurologic manifestations were frequently encountered but these adverse reactions were generally mild. Significant antineoplastic activity in far-advanced and heavily pretreated @entity1 warrants further evaluation of this regimen at an earlier stage of the disease.
